Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions Opens 1600L/1000L reactor stream in Oxford, UK and raises API capacity at Verona, Italy Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit offers increased its global capacity for Active Pharmaceutical Component Manufacture due to increased demand for API, and because of its integrated and extensive candidate-to-IND development answer treat vomiting read more . Dr. Goldman stated, ‘Consumer demand for our top quality, integrated, fully inclusive candidate-to-IND solutions has increased over 300 percent on an annual basis. As part of our strategy of buying our infrastructure, we consequently have opened a 1600L/1000L reactor stream at our renowned API facility in Oxford internationally, UK and elevated throughput at our 400L reactors at our world-class, fully integrated, former huge Pharma R&D center of excellence in Verona, Italy.
We have become very happy to partner with Genetic Analysis in this essential and growing section of the market said Winston Ho, President of Applied BioCode. Further conditions of the strategic permit and partnership agreement were not immediately available.. Applied BioCode signs Permit and offer Agreement with Genetic Evaluation for BMB technology Applied BioCode announced today that this has signed a License and Supply Agreement because of its Barcoded Magnetic Bead technology with Genetic Analysis of Oslo, Norway. The license from Applied BioCode gives Genetic Analysis usage of specific Applied BioCode BMB patents and BioCode analyzers for Molecular Diagnostic tests of microbial imbalances in the GI tract.